Novartis AG's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Selling-General-and-Administrative" stands at 13.31 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value since 03/31/2024.
Novartis AG's third quarter result of 3.31 Billion USD for the item "Selling General and Administrative" represents a decrease of -3.87 percent compared to it's second quarter result.
Also, Novartis AG's third quarter result of 3.31 Billion USD for the item "Selling General and Administrative" represents an increase of 5.55 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Novartis AG's third quarter result of 13.31 Billion USD for the item "Selling General and Administrative" represents an increase of 1.32 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 6.39 percent compared to the value the year prior.
The 1 year change in percent is 6.39.
The 3 year change in percent is -8.10.
The 5 year change in percent is -6.14.
The 10 year change in percent is -7.11.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Selling General and Administrative | 905,699,262,464.00 |
![]() | Johnson & Johnson - Selling General and Administrative | 486,508,953,600.00 |
![]() | AbbVie Inc - Selling General and Administrative | 399,570,305,024.00 |
![]() | Roche Holding AG - Selling General and Administrative | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Selling General and Administrative | 280,205,508,085.11 |